Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 18 and up Women only

Micronutrient supplements to prevent anemia in pregnant women in Tanzania

Official title: Individually Randomized Trial of Higher-dose Iron (60 mg, 45 mg) Compared to Low-dose Iron (30 mg) in Multiple Micronutrient Supplements in Pregnancy on Moderate and Severe Maternal Anemia

Run by George Washington University · NCT06079918 · Data updated 2026-11-12

This study tests whether different amounts of iron in micronutrient supplements can help prevent anemia in pregnant women in Tanzania.

More Pregnancy Related trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexWomen only
Enrollment6381 (estimated)
SponsorGeorge Washington University
Academic / other
Locations1 site (Dar es Salaam)
StatusRecruiting
StartedMarch 3, 2025
Main results expectedMarch 2027
Study endsJune 2027
Registry record updatedJuly 14, 2026
Trial IDNCT06079918 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are pregnant women under 20 weeks gestation, aged 18 years or older, who are planning to stay in Dar es Salaam until six weeks after delivery.

Probably not a fit

Patients with severe anemia, sickle cell disease, or those currently enrolled in another nutritional clinical trial may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of multiple micronutrient supplements (MMS) with varying iron content in preventing moderate to severe anemia among pregnant women in Tanzania. Participants will be randomly assigned to receive MMS containing either 30 mg, 45 mg, or 60 mg of elemental iron. The study aims to determine the optimal iron dosage for maternal health, providing critical data for health policy in Tanzania. The trial will involve pregnant women attending their first antenatal care visit and will track their health outcomes until six weeks post-delivery.

Why it matters

Potential benefit: If successful, this study could lead to improved maternal health and reduced anemia rates among pregnant women in Tanzania.

How similar studies have gone: Previous studies on micronutrient supplementation have shown promising results, indicating that this approach could be effective, though this specific dosage comparison is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Attending first ANC visit at study clinics
* Pregnant women \< 20 weeks gestation by last menstrual period (LMP)
* Aged ≥ 18 years old
* Intending to stay in Dar es Salaam until 6 weeks post delivery
* Provides informed consent

Exclusion Criteria:

* Severe anemia (defined as hemoglobin \< 8.5 g/dL per Tanzania standard of care)
* Sickle cell disease (SS and SC) and hemoglobin C disease (CC) as tested by HemoTypeSC
* Concurrently enrolled in another nutritional clinical trial
* Pregnant women with disability or condition which would impair their ability to provide informed consent and complete study procedures.

Where it's running

  • Muhimbili University of Health and Allied Sciences
    Dar es Salaam, Tanzania
    Recruiting

Study contacts

  • Principal investigator: Blair Wylie, MD, MPH — Columbia University
  • Study coordinator: Emily R Smith, ScD, MPH
  • Email: emilysmith@gwu.edu
  • Phone: 202-994-3589

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.